Vicore Pharma (VCRE) appoints Rob Slack as new Chief Scientific Officer
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Vicore Pharma Holding has appointed Rob Slack, PhD, FRSB as Chief Scientific Officer, succeeding Johan Raud, MD, PhD, who will transition to Senior Advisor. Dr. Slack brings over 20 years of leadership in fibrosis and respiratory translational science, including senior roles at GSK as Vice President and Head of Respiratory Biology and prior service as acting Chief Scientific Officer at Galecto. He has contributed to multiple approved respiratory medicines for asthma, COPD and IPF and has more than 60 scientific publications. As Chief Scientific Officer, he will lead Vicore’s research strategy and development of its next-generation angiotensin II type 2 receptor agonist pipeline, including the lead program buloxibutid, which is in a global 52‑week Phase 2b ASPIRE trial in idiopathic pulmonary fibrosis and holds Orphan Drug and Fast Track designations from the U.S. FDA.
Positive
- None.
Negative
- None.
Key Figures
Industry experience: Over 20 years
Scientific publications: More than 60 publications
ASPIRE trial duration: 52-week
3 metrics
Industry experience
Over 20 years
Dr. Rob Slack’s experience in fibrosis and respiratory translational science
Scientific publications
More than 60 publications
Rob Slack’s academic and scientific track record
ASPIRE trial duration
52-week
Global Phase 2b ASPIRE trial for buloxibutid in IPF
Key Terms
angiotensin II type 2 receptor agonists, idiopathic pulmonary fibrosis, Orphan Drug, Fast Track designation, +1 more
5 terms
angiotensin II type 2 receptor agonists medical
"a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists"
idiopathic pulmonary fibrosis medical
"disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF)"
Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.
Orphan Drug regulatory
"buloxibutid ... has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration"
A drug designated for an orphan disease is a medicine developed to treat a rare condition that affects only a small number of people. Regulators often give these drugs special incentives—such as reduced costs, faster review, and temporary exclusive selling rights—to encourage development, which matters to investors because those incentives can make a small market financially viable and reduce competition, much like a temporary patent on a niche product.
Fast Track designation regulatory
"buloxibutid ... has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
Phase 2b ASPIRE trial medical
"currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF"
FAQ
What management change did Vicore Pharma (VCRE) announce in this 6-K?
Vicore Pharma appointed Rob Slack, PhD, FRSB, as Chief Scientific Officer, succeeding Johan Raud, MD, PhD, who will become Senior Advisor. The change realigns scientific leadership while keeping Raud engaged in an advisory role.
What experience does new Vicore Pharma (VCRE) CSO Rob Slack bring?
Rob Slack has over 20 years of drug discovery leadership across biotech and large pharma. He previously served as Vice President and Head of Respiratory Biology at GSK and acting Chief Scientific Officer at Galecto, and has contributed to several approved respiratory medicines.
What will Rob Slack’s role be at Vicore Pharma (VCRE)?
As Chief Scientific Officer, Rob Slack will lead Vicore’s research strategy and development of its next-generation angiotensin II type 2 receptor agonist pipeline. This includes guiding scientific efforts behind lead candidate buloxibutid and broader respiratory and fibrotic disease programs.
What is Vicore Pharma’s lead program buloxibutid mentioned in the 6-K?
Buloxibutid is an oral small molecule angiotensin II type 2 receptor agonist being developed for idiopathic pulmonary fibrosis. It has received Orphan Drug and Fast Track designations from the U.S. FDA and is in a global 52-week Phase 2b ASPIRE trial.
How will former CSO Johan Raud remain involved with Vicore Pharma (VCRE)?
Johan Raud, MD, PhD, will transition from Chief Scientific Officer to Senior Advisor. He will continue supporting Vicore Pharma through key upcoming milestones, contributing his long-standing experience in drug discovery and knowledge of the company’s science.
What therapeutic focus does Vicore Pharma (VCRE) highlight in this filing?
Vicore Pharma focuses on angiotensin II type 2 receptor agonists with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis. The company emphasizes the mechanism’s breadth across a wide range of respiratory and fibrotic indications.